Xianbiao Xie
YOU?
Author Swipe
View article: Treatment of benign lesions of the proximal femur in young pediatric patients using adult 3.5 mm proximal humerus locking plates
Treatment of benign lesions of the proximal femur in young pediatric patients using adult 3.5 mm proximal humerus locking plates Open
This study aimed to assess the efficacy of using adult 3.5 mm proximal humerus locking plates (PHLPs) for treating benign proximal femur lesions in skeletally immature pediatric patients. Between 2011 and 2021, 22 skeletally immature pedia…
View article: Troxerutin suppresses the stemness of osteosarcoma via the CD155/SRC/β-catenin signaling axis
Troxerutin suppresses the stemness of osteosarcoma via the CD155/SRC/β-catenin signaling axis Open
View article: Targeting NAT10 inhibits osteosarcoma progression via ATF4/ASNS-mediated asparagine biosynthesis
Targeting NAT10 inhibits osteosarcoma progression via ATF4/ASNS-mediated asparagine biosynthesis Open
View article: A diagnostic signature developed based on the necroptosis-related genes and its association with immune infiltration in osteosarcoma
A diagnostic signature developed based on the necroptosis-related genes and its association with immune infiltration in osteosarcoma Open
View article: The survival and complication profiles of the Compress® Endoprosthesis: A systematic review and meta-analysis
The survival and complication profiles of the Compress® Endoprosthesis: A systematic review and meta-analysis Open
CPS's innovative spring system promotes bone ingrowth by providing immediate and high-compression fixation, thereby reducing the risk of aseptic loosening caused by stress shielding and particle-induced osteolysis. CPS requires less residu…
View article: Tumor-informed deep sequencing of ctDNA detects minimal residual disease and predicts relapse in osteosarcoma
Tumor-informed deep sequencing of ctDNA detects minimal residual disease and predicts relapse in osteosarcoma Open
The Grants of National Natural Science Foundation of China (No. 82072964, 82072965, 82203798, 82203026), the Natural Science Foundation of Guangdong (No. 2023A1515012659, 2023A1515010302), and the Regional Combination Project of Basic and …
View article: Age-dependent molecular variations in osteosarcoma: implications for precision oncology across pediatric, adolescent, and adult patients
Age-dependent molecular variations in osteosarcoma: implications for precision oncology across pediatric, adolescent, and adult patients Open
Background Osteosarcoma is a leading subtype of bone tumor affecting adolescents and adults. Comparative molecular characterization among different age groups, especially in pediatric, adolescents and adults, is scarce. Methods We collecte…
View article: Comparison of oncological and functional outcomes in Lower-limb osteosarcoma pediatric patients: a large single-center retrospective cohort study
Comparison of oncological and functional outcomes in Lower-limb osteosarcoma pediatric patients: a large single-center retrospective cohort study Open
Objective: Treating pediatric osteosarcoma in long bones is challenging due to skeletal immaturity, which restricts the generalizability of insights derived from adult patients. Are there disparities in outcomes? How should surgical protoc…
View article: Editor's Note: Combining EGFR and mTOR Blockade for the Treatment of Epithelioid Sarcoma
Editor's Note: Combining EGFR and mTOR Blockade for the Treatment of Epithelioid Sarcoma Open
View article: Construction of an ER stress-related prognostic signature for predicting prognosis and screening the effective anti-tumor drug in osteosarcoma
Construction of an ER stress-related prognostic signature for predicting prognosis and screening the effective anti-tumor drug in osteosarcoma Open
View article: Additional file 1 of Construction of an ER stress-related prognostic signature for predicting prognosis and screening the effective anti-tumor drug in osteosarcoma
Additional file 1 of Construction of an ER stress-related prognostic signature for predicting prognosis and screening the effective anti-tumor drug in osteosarcoma Open
Additional file 1: Table S1. Summary of 62 osteosarcoma patients clinical information.
View article: Ceramide metabolism-related prognostic signature and immunosuppressive function of ST3GAL1 in osteosarcoma
Ceramide metabolism-related prognostic signature and immunosuppressive function of ST3GAL1 in osteosarcoma Open
Osteosarcoma is the most common primary malignant bone tumor with elevated disability and mortality rates in children and adolescents and the therapeutic effect for osteosarcoma has remained stagnant in the past 30 years. Emerging evidence…
View article: Figure S3 from Degalactotigonin, a Natural Compound from <i>Solanum nigrum L</i>., Inhibits Growth and Metastasis of Osteosarcoma through GSK3β Inactivation–Mediated Repression of the Hedgehog/Gli1 Pathway
Figure S3 from Degalactotigonin, a Natural Compound from <i>Solanum nigrum L</i>., Inhibits Growth and Metastasis of Osteosarcoma through GSK3β Inactivation–Mediated Repression of the Hedgehog/Gli1 Pathway Open
Pathological changes were observed in vital organs (heart, livers, kidney and lung) from mice treated with DGT, as detected by HE staining.
View article: Supplementary Methods, Table 1, Figures 1-4 from Activated MET Is a Molecular Prognosticator and Potential Therapeutic Target for Malignant Peripheral Nerve Sheath Tumors
Supplementary Methods, Table 1, Figures 1-4 from Activated MET Is a Molecular Prognosticator and Potential Therapeutic Target for Malignant Peripheral Nerve Sheath Tumors Open
Supplementary Methods, Table 1, Figures 1-4 from Activated MET Is a Molecular Prognosticator and Potential Therapeutic Target for Malignant Peripheral Nerve Sheath Tumors
View article: Supplementary Data Legend from Targeting Super-Enhancer–Associated Oncogenes in Osteosarcoma with THZ2, a Covalent CDK7 Inhibitor
Supplementary Data Legend from Targeting Super-Enhancer–Associated Oncogenes in Osteosarcoma with THZ2, a Covalent CDK7 Inhibitor Open
Supplementary data legend
View article: Data from Degalactotigonin, a Natural Compound from <i>Solanum nigrum L</i>., Inhibits Growth and Metastasis of Osteosarcoma through GSK3β Inactivation–Mediated Repression of the Hedgehog/Gli1 Pathway
Data from Degalactotigonin, a Natural Compound from <i>Solanum nigrum L</i>., Inhibits Growth and Metastasis of Osteosarcoma through GSK3β Inactivation–Mediated Repression of the Hedgehog/Gli1 Pathway Open
Purpose: Agents extracted from natural sources with antitumor property have attracted considerable attention from researchers and clinicians because of their safety, efficacy, and immediate availability. Degalactotigonin (DGT), extr…
View article: Data from Combining EGFR and mTOR Blockade for the Treatment of Epithelioid Sarcoma
Data from Combining EGFR and mTOR Blockade for the Treatment of Epithelioid Sarcoma Open
Purpose: Molecular deregulations underlying epithelioid sarcoma (ES) progression are poorly understood yet critically needed to develop new therapies. Epidermal growth factor receptor (EGFR) is overexpressed in ES; using preclinical…
View article: Data from Combining EGFR and mTOR Blockade for the Treatment of Epithelioid Sarcoma
Data from Combining EGFR and mTOR Blockade for the Treatment of Epithelioid Sarcoma Open
Purpose: Molecular deregulations underlying epithelioid sarcoma (ES) progression are poorly understood yet critically needed to develop new therapies. Epidermal growth factor receptor (EGFR) is overexpressed in ES; using preclinical…
View article: Figure S2 from Targeting Super-Enhancer–Associated Oncogenes in Osteosarcoma with THZ2, a Covalent CDK7 Inhibitor
Figure S2 from Targeting Super-Enhancer–Associated Oncogenes in Osteosarcoma with THZ2, a Covalent CDK7 Inhibitor Open
Comparative quantification of tumor weight and lung metastasis in CDK7 knockdown and control group.
View article: Figure S7 from Degalactotigonin, a Natural Compound from <i>Solanum nigrum L</i>., Inhibits Growth and Metastasis of Osteosarcoma through GSK3β Inactivation–Mediated Repression of the Hedgehog/Gli1 Pathway
Figure S7 from Degalactotigonin, a Natural Compound from <i>Solanum nigrum L</i>., Inhibits Growth and Metastasis of Osteosarcoma through GSK3β Inactivation–Mediated Repression of the Hedgehog/Gli1 Pathway Open
IHC analyses of the selected proteins indicated that the DGT-treated tumor tissues from the mice in Fig. 4A
View article: Table S1 and S2 from Degalactotigonin, a Natural Compound from <i>Solanum nigrum L</i>., Inhibits Growth and Metastasis of Osteosarcoma through GSK3β Inactivation–Mediated Repression of the Hedgehog/Gli1 Pathway
Table S1 and S2 from Degalactotigonin, a Natural Compound from <i>Solanum nigrum L</i>., Inhibits Growth and Metastasis of Osteosarcoma through GSK3β Inactivation–Mediated Repression of the Hedgehog/Gli1 Pathway Open
Table S1: Primers for real-time PCR. Table S2: Patient characteristics at initial diagnosis.
View article: Figure S3 from Degalactotigonin, a Natural Compound from <i>Solanum nigrum L</i>., Inhibits Growth and Metastasis of Osteosarcoma through GSK3β Inactivation–Mediated Repression of the Hedgehog/Gli1 Pathway
Figure S3 from Degalactotigonin, a Natural Compound from <i>Solanum nigrum L</i>., Inhibits Growth and Metastasis of Osteosarcoma through GSK3β Inactivation–Mediated Repression of the Hedgehog/Gli1 Pathway Open
Pathological changes were observed in vital organs (heart, livers, kidney and lung) from mice treated with DGT, as detected by HE staining.
View article: Figure S5 from Degalactotigonin, a Natural Compound from <i>Solanum nigrum L</i>., Inhibits Growth and Metastasis of Osteosarcoma through GSK3β Inactivation–Mediated Repression of the Hedgehog/Gli1 Pathway
Figure S5 from Degalactotigonin, a Natural Compound from <i>Solanum nigrum L</i>., Inhibits Growth and Metastasis of Osteosarcoma through GSK3β Inactivation–Mediated Repression of the Hedgehog/Gli1 Pathway Open
Clinical relevance of Gli1 expression in human osteosarcoma specimens.
View article: Figure S7 from Degalactotigonin, a Natural Compound from <i>Solanum nigrum L</i>., Inhibits Growth and Metastasis of Osteosarcoma through GSK3β Inactivation–Mediated Repression of the Hedgehog/Gli1 Pathway
Figure S7 from Degalactotigonin, a Natural Compound from <i>Solanum nigrum L</i>., Inhibits Growth and Metastasis of Osteosarcoma through GSK3β Inactivation–Mediated Repression of the Hedgehog/Gli1 Pathway Open
IHC analyses of the selected proteins indicated that the DGT-treated tumor tissues from the mice in Fig. 4A
View article: Supplementary Data Legend from Targeting Super-Enhancer–Associated Oncogenes in Osteosarcoma with THZ2, a Covalent CDK7 Inhibitor
Supplementary Data Legend from Targeting Super-Enhancer–Associated Oncogenes in Osteosarcoma with THZ2, a Covalent CDK7 Inhibitor Open
Supplementary data legend
View article: Figure S5 from Targeting Super-Enhancer–Associated Oncogenes in Osteosarcoma with THZ2, a Covalent CDK7 Inhibitor
Figure S5 from Targeting Super-Enhancer–Associated Oncogenes in Osteosarcoma with THZ2, a Covalent CDK7 Inhibitor Open
Specificity and efficiency of RT-qPCR primers.
View article: Figure S4 from Degalactotigonin, a Natural Compound from <i>Solanum nigrum L</i>., Inhibits Growth and Metastasis of Osteosarcoma through GSK3β Inactivation–Mediated Repression of the Hedgehog/Gli1 Pathway
Figure S4 from Degalactotigonin, a Natural Compound from <i>Solanum nigrum L</i>., Inhibits Growth and Metastasis of Osteosarcoma through GSK3β Inactivation–Mediated Repression of the Hedgehog/Gli1 Pathway Open
The weights of lungs from mice described in Figure 5E and F.
View article: Figure S2 from Degalactotigonin, a Natural Compound from <i>Solanum nigrum L</i>., Inhibits Growth and Metastasis of Osteosarcoma through GSK3β Inactivation–Mediated Repression of the Hedgehog/Gli1 Pathway
Figure S2 from Degalactotigonin, a Natural Compound from <i>Solanum nigrum L</i>., Inhibits Growth and Metastasis of Osteosarcoma through GSK3β Inactivation–Mediated Repression of the Hedgehog/Gli1 Pathway Open
The effects of DGT on the mice weight.
View article: Table S1 from Targeting Super-Enhancer–Associated Oncogenes in Osteosarcoma with THZ2, a Covalent CDK7 Inhibitor
Table S1 from Targeting Super-Enhancer–Associated Oncogenes in Osteosarcoma with THZ2, a Covalent CDK7 Inhibitor Open
Super-enhancer analysis based on H3K27Ac ChIP-seq in U2-OS and SJSA-1 cells.
View article: Figure S3 from Targeting Super-Enhancer–Associated Oncogenes in Osteosarcoma with THZ2, a Covalent CDK7 Inhibitor
Figure S3 from Targeting Super-Enhancer–Associated Oncogenes in Osteosarcoma with THZ2, a Covalent CDK7 Inhibitor Open
Enrichment analysis of THZ2-sensitive genes in osteosarcoma.